WELCOME to epgonline.org

Access trusted, independent sources of clinical content for the United Kingdom as well as other regions. Registration is quick and simple, providing you with unlimited access to all content and features.
 

Latest News

Added 2 days ago Drug news

FDA advisory committee recommends once-weekly semaglutide for type 2 diabetes. - Novo Nordisk.

Novo Nordisk announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the FDA voted 16-0 in favour of...

Added 2 days ago Drug news

NICE recommends Opdivo to treat head and neck cancer.- BMS.

When the National Institute for Health and Care Excellence (NICE) first reviewed Opdivo (nivolumab), it found that the evidence for...

Added 2 days ago Drug news

FDA approves Yescarta to treat large B-cell lymphoma.- Kite/Gilead Sciences.

Kite, a Gilead Company, announced that the FDA has granted regular approval to Yescarta (axicabtagene ciloleucel), the first chimeric antigen...

Search all news articles
 

WHAT'S ON THE HORIZON?

Penny Staton

Improving non-alcoholic steatohepatitis care – is the finishing line in sight?

Posted 24 days ago

An intense race is going on right now in non-alcoholic steatohepatitis (NASH) research. A number of significant players within the pharmaceutical and biotechnology sectors are competing to develop the first major therapeutic advance in treatment for this neglected condition. But should we consider it more of a relay race? Could improved diagnosis, disease assessment and even combination therapy be the key to victory over this increasingly prevalent disease?

Marshall Pearce

Left ventricular assist devices – A viable therapeutic option for heart failure?

Posted 4 months ago

Alongside a pharmacological strategy to aid myocardial recovery, LVADs may prove to have a significant role to play in the ever-growing problem of heart failure. Although LVADs are not new onto the scene, the advance of technology – smaller, more efficient devices with better reliability and potentially transcutaneous power transfer – means we may be on the cusp of seeing many more deployed to tackle heart failure.

Marshall Pearce

Cancer immunotherapies

Posted 6 months ago

It was the winner of the 1908 Nobel prize for medicine, Paul Ehrlich, who is first credited with discussing the concept of a “magic bullet”, able to target specific cells without damaging healthy tissue. With the advent of immunotherapy, as well as antibody-drug conjugates, we are beginning to realise this vision.

Marshall Pearce

Antibody-drug conjugates (ADCs)

Posted 6 months ago

Over the past couple of decades, there have been advances in a class of drugs which for a long time was purely theoretical: antibody-drug conjugates (ADCs). The concept underlying ADCs is elegant – what if it were possible to ‘target’ particular groups of cells with a cytotoxic agent, rather than exposing every cell of the body to it?

Latest Journal Abstracts

The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.

Introduction: Lumacaftor-ivacaftor is indicated for treatment of cystic fibrosis (CF) in patients homozygous for the Phe-508del cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations.

Added 2 days ago

Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.

Introduction: Cystic Fibrosis (CF) is an autosomal recessive disease affecting up to 90,000 people worldwide. Approximately 73% of patients are homozygous for the F508del cystic fibrosis transmembrane conductance regulator...

Added 2 days ago

Discovery and preclinical development of dasabuvir for the treatment of hepatitis C infection.

Introduction: Hepatitis C virus (HCV) is a leading cause of liver-related morbidity and mortality. Positively, the introduction of new directly-acting antivirals (DAAs) have led to dramatic...

Added 4 days ago

Search all journal articles
 

Latest Guidelines

Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Evidence shows that rectal cancer is distinct from colon cancer, with different aetiologies and risk factors possibly reflecting different environmental exposures.

Added 4 years ago

Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Cervical cancer is the second most commonly diagnosed cancer and the third leading cause of cancer death among females in less developed countries. These updated guidelines focus on the management...

Added 5 years ago

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Mantle cell lymphoma is a relatively uncommon subtype of lymphoid malignancy and is more often found in males than in females. These updated ESMO guidelines provide treatment recommendations...

Added 3 years ago

Search all guidelines
 

Latest Clinical Trials

Multiple Cardiac Sensors for the Management of Heart Failure (MANAGE-HF)

The MANAGE-HF study is a multi-center, global, prospective, open label, multi-phase trial intended to evaluate the clinical efficacy of the HeartLogic heart failure diagnostic feature.

Added 25 days ago

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

The study evaluates the efficacy of fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI) to reduce the annual rate of moderate and severe exacerbations compared with dual therapy...

Added 1 month ago

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

This study involves a course of radiation to up to 5 tumors in the participant's liver followed by systemic therapy (Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body).

Added 6 months ago

Search all clinical trials